Cita APA

M, O., JW, D., N, D., ES, M., A, N., K, S., . . . E, M. (2023). Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).

Citación estilo Chicago

M, Oskoui, et al. Two-year Efficacy and Safety of Risdiplam in Patients With Type 2 or Non-ambulant Type 3 Spinal Muscular Atrophy (SMA). 2023.

Cita MLA

M, Oskoui, et al. Two-year Efficacy and Safety of Risdiplam in Patients With Type 2 or Non-ambulant Type 3 Spinal Muscular Atrophy (SMA). 2023.